PMID- 36192621
OWN - NLM
STAT- MEDLINE
DCOM- 20221005
LR  - 20221201
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 12
IP  - 1
DP  - 2022 Oct 3
TI  - Adverse events of recreational cannabis use during pregnancy reported to the 
      French Addictovigilance Network between 2011 and 2020.
PG  - 16509
LID - 10.1038/s41598-022-19197-2 [doi]
LID - 16509
AB  - Cannabis is the main illicit psychoactive substance used by pregnant women in 
      France. The aim of the present national survey was to describe adverse events 
      (AEs) of recreational cannabis use during pregnancy reported to the French 
      Addictovigilance Network (FAN). Spontaneous reports (SRs) of AEs related to 
      recreational cannabis use during pregnancy were collected by the FAN between 
      01/01/2011 and 31/01/2021 (excluding cannabidiol and synthetic cannabinoids). 
      Over the study period, 160 SRs involved cannabis use alone or in association with 
      tobacco (59% of all SRs) which increased. Among the 175 maternal AEs, the most 
      commons were psychiatric AEs experienced by 96 (64.9%) women, in particular 
      cannabis use disorders (n = 89, 60.1%), dependence (n = 54, 36.5%) and abuse 
      (n = 21, 14.2%). Among the 57 fetal AEs, the most common were heart rhythm 
      disorders that affected 25 (16.9%) fetuses and intrauterine growth restriction 
      (IUGR) (n = 20, 13.5%). Among the 140 neonatal AEs, the most common were IUGR 
      experienced by 39 (26.3%) newborns and prematurity (n = 32, 21.6%). Twelve cases 
      of congenital malformations were observed and 4 intrauterine/neonatal deaths. 
      Furthermore, some of these AEs (n = 13) were unexpected. Cannabis use during 
      pregnancy has problematic consequences for both mothers and infants who need 
      close monitoring.
CI  - (c) 2022. The Author(s).
FAU - Bouquet, Emilie
AU  - Bouquet E
AD  - Department of Clinical Pharmacology, Addictovigilance Center, Poitiers University 
      Hospital, 2 rue de la Miletrie, 86 021, Poitiers, France. 
      emilie.bouquet@chu-poitiers.fr.
AD  - Experimental and Clinical Neurosciences Laboratory, INSERM U-1084, University of 
      Poitiers, Poitiers, France. emilie.bouquet@chu-poitiers.fr.
FAU - Eiden, Celine
AU  - Eiden C
AD  - Addictovigilance Center, Montpellier University Hospital, Montpellier, France.
FAU - Fauconneau, Bernard
AU  - Fauconneau B
AD  - Department of Clinical Pharmacology, Addictovigilance Center, Poitiers University 
      Hospital, 2 rue de la Miletrie, 86 021, Poitiers, France.
FAU - Pion, Charlotte
AU  - Pion C
AD  - French National Agency for Medicines and Health Products Safety (ANSM), 
      Saint-Denis, France.
CN  - French Addictovigilance Network (FAN)
FAU - Pain, Stephanie
AU  - Pain S
AD  - Department of Clinical Pharmacology, Addictovigilance Center, Poitiers University 
      Hospital, 2 rue de la Miletrie, 86 021, Poitiers, France.
AD  - Experimental and Clinical Neurosciences Laboratory, INSERM U-1084, University of 
      Poitiers, Poitiers, France.
FAU - Perault-Pochat, Marie-Christine
AU  - Perault-Pochat MC
AD  - Department of Clinical Pharmacology, Addictovigilance Center, Poitiers University 
      Hospital, 2 rue de la Miletrie, 86 021, Poitiers, France.
AD  - Experimental and Clinical Neurosciences Laboratory, INSERM U-1084, University of 
      Poitiers, Poitiers, France.
LA  - eng
PT  - Journal Article
DEP - 20221003
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Cannabinoid Receptor Agonists)
RN  - 0 (Hallucinogens)
RN  - 19GBJ60SN5 (Cannabidiol)
SB  - IM
MH  - *Cannabidiol
MH  - Cannabinoid Receptor Agonists
MH  - *Cannabis/adverse effects
MH  - Female
MH  - Fetal Growth Retardation
MH  - *Hallucinogens
MH  - Humans
MH  - Infant
MH  - Infant, Low Birth Weight
MH  - Infant, Newborn
MH  - Male
MH  - Pregnancy
MH  - *Substance-Related Disorders
PMC - PMC9530152
COIS- The authors declare no competing interests.
FIR - Louise, Carton
IR  - Louise C
FIR - Cecile, Chevalier
IR  - Cecile C
FIR - Amelie, Daveluy
IR  - Amelie D
FIR - Christine, Fournier-Choma
IR  - Christine FC
FIR - Julie, Heredia
IR  - Julie H
FIR - Marion, Istvan
IR  - Marion I
FIR - Emilie, Jouanjus
IR  - Emilie J
FIR - Helene, Peyriere
IR  - Helene P
FIR - Liselotte, Pochard
IR  - Liselotte P
FIR - Bruno, Revol
IR  - Bruno R
FIR - Veronique, Savignat
IR  - Veronique S
FIR - Juliana, Tournebize
IR  - Juliana T
EDAT- 2022/10/04 06:00
MHDA- 2022/10/06 06:00
PMCR- 2022/10/03
CRDT- 2022/10/03 23:36
PHST- 2022/05/03 00:00 [received]
PHST- 2022/08/25 00:00 [accepted]
PHST- 2022/10/03 23:36 [entrez]
PHST- 2022/10/04 06:00 [pubmed]
PHST- 2022/10/06 06:00 [medline]
PHST- 2022/10/03 00:00 [pmc-release]
AID - 10.1038/s41598-022-19197-2 [pii]
AID - 19197 [pii]
AID - 10.1038/s41598-022-19197-2 [doi]
PST - epublish
SO  - Sci Rep. 2022 Oct 3;12(1):16509. doi: 10.1038/s41598-022-19197-2.